Quanterix wins FDA breakthrough nod for neurofilament light chain plasma test

Quanterix (Nasdaq:QTRX) announced today that it received FDA breakthrough device designation for a multiple sclerosis (MS) diagnostic.

Billerica, Massachusetts-based Quanterix designed its Simoa neurofilament light chain (NfL) plasma test as a prognostic aid in assessing the risk of disease activity in patients diagnosed with relapsing-remitting MS (RRMS).

According to a news release, the company designed the digital immunoassay to quantitatively measure NfL in human serum and plasma. It has shown promise in conjunction with clinical, imaging and laboratory findings as an aid in identifying RRMS patients who are at lower or higher risk for relapse within four years, offering assistance in tailoring the therapeutic approach to more effectively treat the disease.

The breakthrough nod follows the publishing of a large-scale, international study in The Lancet Neurology. The study demonstrated that the ultra-sensitive Simoa technology helped establish a new m…

Read more
  • 0

Quanterix prices $84.8M public offering

Quanterix announced (NSDQ:QTRX) announced that it priced its previously announced underwritten public offering of common stock at $32 per share.

Billerica, Mass.-based Quanterix is selling 2,651,108 shares of its common stock and expects to collect gross proceeds of approximately $84.8 million. Quanterix also granted underwriters a 30-day option to purchase up to 397,666 additional shares at the public offering price.

The digital biomarker analysis technology developer expects the offering to close on Aug. 11, 2020, subject to customary closing conditions, according to a news release. SVB Leerink and Cowen are acting as joint bookrunning managers for the offering. Canaccord Genuity is acting as co-manager for the offering.

Quanterix did not reveal its intended use of proceeds. Currently, its Simoa digital health solution is used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious …

Read more
  • 0